ADALIMUMAB

Information current as at: 1 July 2026

PBAC meeting date: November 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Amgevita®
Form and strength:: Injection 20 mg in 0.2 mL pre-filled syringe

Injection 40 mg in 0.4 mL pre-filled syringe

Injection 40 mg in 0.4 mL pre-filled pen

Injection 80 mg in 0.8 mL pre-filled pen
Submission sponsor:: AMGEN AUSTRALIA PTY LIMITED
Condition/indication: (therapeutic use): Immune-mediated inflammatory disease
Listing requested:: To request a broad listing of Amgevita (for the higher concentration forms that were recommended by the PBAC at its March 2026 meeting) for the treatment of immune-mediated inflammatory disease .
Funding program:: PBS General Schedule
Request authority level:: Authority Required (STREAMLINED)
PBAC Submission type:: Change to existing listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: November 2026 PBAC meeting
2Opportunity for consumer comment:: Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a1261

Page last updated

23 July 2026

v.9.19